Dr. Weinberg joined the company in 2011 as the global therapeutic area head in CNS and Pain. He has more than 14 years of experience in the pharmaceutical industry, working across multiple therapeutic areas. Prior to Astellas he was at Lundbeck, where he focused on CNS.
Dr. McGarry has more than 25 years of experience in the pharmaceutical industry, including positions in clinical development and medical affairs, and served as vice president, Worldwide Safety at Pfizer. For the past 13 years, she has worked as an independent consultant, providing pharmacovigilance, clinical, and regulatory strategic consulting services.
"Since its inception in 2008, APGD has been a driving force in Astellas' mission of developing innovative medicines for patients in need, said Dr. Sef Kurstjens, chief medical officer of Astellas and president of APGD. "We are thrilled to be promoting Mark and bringing Robin onto the Astellas team to further that mission."